ACCELERATES ELIMINATION OF ALCOHOL FROM BLOOD AND TISSUES, TO HELP RESTORE THE FUNCTIONAL STRUCTURE OF THE LIVER AND TO RELIEVE NEURO-PSYCHOLOGICAL DISORDERS ASSOCIATED WITH ALCOHOL INTOXICATION. IT INDUCES ALTERATIONS OF ALCOHOL METABOLISM IN RATS. IT INCREASES THE ACTIVITY OF ACETALDEHYDE DEHYDROGENASE AND PREVENTS THE DECREASE IN ALCOHOL DEHYDROGENASE ACTIVITY SHOWN IN CHRONIC ETHANOL FED RATS. ITS ADMINISTRATION ACCELERATES PLASMA AND URINARY CLEARANCE OF ETHANOL AND ACETALDEHYDE IN A DOSE-DEPENDENT MANNER. METADOXINE SIGNIFICANTLY INHIBITS THE INCREASE OF FATTY ACID ESTERS IN THE LIVER OF ETHANOL TREATED RATS, RESTORING THE CORRECT RATIO BETWEEN HEPATIC SATURATED AND UNSATURATED FATTY SUBSTANCES. AT 160 MG/KG, METADOXINE ALSO PREVENTED THE FORMATION OF FATTY LIVER IN 50% OF RATS EXPOSED TO A DOSE OF ETHANOL ABLE TO INDUCE FATTY LIVER IN 100% OF THE RATS IN THE CONTROL GROUP. IT PREVENTS GLUTATHIONE DEPLETION, LIPID PEROXIDATION DAMAGE, COLLAGEN DEPOSITION AND TNF ALFA SECRETIONS INDUCED BY ALCOHOL AND
ACETALDEHYDE IN HEPATOCYTES AND HEPATIC STELLATE CELLS. THESE MECHANISMS COULD BE IMPLICATED IN THE ABILITY OF METADOXINE TO PREVENT HEPATIC NECROINFLAMMATION, FIBROSIS AND PROGRESSION TO CIRRHOSIS IN RATS CHRONICALLY EXPOSED TO HEPATOTOXIC AGENTS